drugset / Trial / NCT02609945

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945

Phase 1 Completed 21 enrolled Acorda Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.

Timeline

Start
2015-11
Primary completion
2015-12
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolmitriptan Small molecule Oral

Indications